Dulaglutide (brand name Trulicity) is a once-weekly injectable GLP-1 receptor agonist used to improve blood sugar control in type 2 diabetes and to reduce the risk of serious cardiovascular events in adults with established heart disease or multiple cardiac risk factors.
What it does
Dulaglutide mimics GLP-1 (glucagon-like peptide-1), a hormone your gut releases after meals. Its amino acid sequence is 90% identical to the naturally occurring human form PubMed 40798976. It binds to GLP-1 receptors on pancreatic beta cells — the cells that produce insulin — and triggers a rise in cyclic AMP (cAMP), a signaling molecule that tells those cells to release insulin. Critically, this insulin release is glucose-dependent: the signal only fires when blood sugar is elevated, which is why dulaglutide by itself carries a low risk of hypoglycemia (dangerously low blood sugar) PubMed 31600725.
Beyond insulin, dulaglutide suppresses glucagon — the hormone that tells your liver to dump glucose into the bloodstream — and slows gastric emptying (how fast food leaves your stomach), both of which blunt post-meal blood sugar spikes PubMed 40798976. The slowed gastric emptying also contributes to reduced appetite and, for many users, meaningful weight loss. Dulaglutide's half-life of roughly five days allows once-weekly dosing, a design advantage over older short-acting GLP-1 agents PubMed 40798976.
What the evidence shows
Glycemic control in type 2 diabetes Strong human trial evidence across multiple large randomized controlled trials
Dulaglutide consistently lowers HbA1c (a three-month average of blood sugar levels) when added to existing diabetes regimens. A meta-analysis of GLP-1 analogues added to metformin found meaningful HbA1c reductions versus placebo and comparable or superior results to DPP-4 inhibitors PubMed 30394576. A 2025 randomized trial comparing a dulaglutide biosimilar to the reference product in Chinese adults with type 2 diabetes confirmed equivalent efficacy and safety, reinforcing the robustness of the original clinical data PubMed 40214296. Among GLP-1 agents, dulaglutide sits in the mid-range for HbA1c reduction; semaglutide and newer triple agonists like retatrutide show numerically larger effects PubMed 30047216 PubMed 37086147.
Cardiovascular risk reduction Strong human evidence from the REWIND outcomes trial; ongoing research expanding the picture
The REWIND trial — a large cardiovascular outcomes study — showed dulaglutide significantly reduced the composite risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults with type 2 diabetes who had established cardiovascular disease or multiple risk factors PubMed 31600725. This cardiovascular benefit is a core FDA-approved indication, not merely an off-label hope. Ongoing trials such as INTERCEPT-ASCVD are continuing to map GLP-1-class cardiovascular effects across broader populations NCT07417618.
Weight loss and appetite reduction Solid human evidence for modest weight loss; not approved as a weight-loss drug
Dulaglutide produces modest but consistent body weight reductions — typically 2–4 kg in trials — driven by slowed gastric emptying and central appetite suppression PubMed 30394576. This is meaningfully less than the weight loss seen with higher-dose semaglutide or emerging triple agonists PubMed 37086147 PubMed 36354040. For patients whose primary goal is weight loss rather than glycemic control, other agents in this class have a stronger track record.
Use in type 2 diabetes with inflammatory bowel disease Early-stage investigation; no established conclusions yet
At least one registered trial is actively exploring GLP-1 analogues including dulaglutide in overweight type 2 diabetic patients with chronic inflammatory bowel disease NCT05196958. The rationale involves both metabolic and potentially anti-inflammatory effects, but this remains investigational with no published results to cite.
How it's used
In clinical studies and prescribing practice, dulaglutide is administered as a subcutaneous (under-the-skin) injection once weekly. The starting dose is typically 0.75 mg per week; this is often escalated to 1.5 mg after four weeks based on tolerability and response. Higher doses of 3 mg and 4.5 mg are approved and have been studied using pharmacokinetic modeling to characterize nausea and vomiting profiles at each step PubMed 37853524. Injection sites include the abdomen, thigh, or upper arm; sites should be rotated. The long half-life of approximately five days means the day of the week for injection is flexible, though consistency helps with tolerability. In studies and self-reported protocols, doses range from 0.75 mg to 4.5 mg weekly depending on the clinical target.
Side effects and safety
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These are dose-dependent and tend to peak during the first few weeks, then improve — a pattern well-characterized in clinical modeling PubMed 37853524. Decreased appetite is also common and is part of the drug's mechanism. Hypoglycemia is rare when dulaglutide is used alone but becomes a real risk when combined with insulin or sulfonylureas. Injection site reactions (redness, itching) occur in a minority of users.
More serious but uncommon risks include pancreatitis (inflammation of the pancreas) — dulaglutide should be avoided in anyone with a history of pancreatitis. There is a boxed warning for thyroid C-cell tumors based on rodent data; dulaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). The relevance of the rodent thyroid findings to humans remains uncertain. Severe gastroparesis (paralyzed stomach) is a relative contraindication because slowing gastric emptying further can worsen the condition. Long-term safety data beyond the trial windows — particularly for populations using GLP-1 agents for extended periods off-label — are still accumulating PubMed 40798976.
Bottom line
Dulaglutide has a well-established evidence base for blood sugar control and cardiovascular risk reduction in type 2 diabetes, backed by large outcome trials. Its once-weekly convenience and favorable hypoglycemia profile are genuine advantages, though it produces less weight loss than newer agents in the class. It is not a fit for anyone with a history of MTC, MEN 2, pancreatitis, or severe gastroparesis.